ArticleScientific reports2025
MIEN1 promoter deletion leads to impaired migration and invasion potential via actin cytoskeleton rearrangement in colorectal cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comprehensive analysis of liquid-liquid phase separation-related genes in osteosarcoma: implications for prognosis, immune infiltration and drug sensitivity.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Colorectal cancer (CRC) is a leading cause of cancer-associated mortality worldwide. Although early-stage CRC is responsive to surgical resection, advanced metastatic disease poses formidable treatment obstacles, triggering an alarming decline in the survival rates of patients. Hence, studying the mechanisms underlying CRC progression and identifying novel therapeutic targets are critical for early diagnosis and treatment. The migration and invasion enhancer 1 (MIEN1) protein plays a pivotal role in tumor invasion and migration across various cancer types. In CRC, the predominant upregulation of MIEN1 in cancerous tissues is closely associated with invasive behavior; however, the precise mechanism driving the metastasis remains unexplored. In this study, we investigate the role of MIEN1 in CRC by generating a CRISPR-Cas9 mediated promoter knockout in HT29 CRC cell-line. The effects of MIEN1 deletion on critical biological processes and molecular pathways, including cell adhesion, migration, and invasion, were investigated using functional assays. RNA sequencing analysis indicated alterations in actin cytoskeleton rearrangement, ultimately manifesting as differences in cellular migration and invasion potential. Signaling molecules essential for actin remodeling, such as phosphorylated FAK (pFAK-Y397) and phosphorylated cofilin (pCofilin-S3), exhibited distinct differences in their cellular localization, implicating the role of MIEN1 in modulating these key proteins. Our findings emphasize the involvement of MIEN1in diverse signaling pathways responsible for CRC migration, with its deletion leading to the disruption of several biological processes, particularly actin cytoskeleton rearrangement, which is crucial for metastasis. Therefore, targeting MIEN1 may be an effective therapeutic strategy against CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.